Press release - 01/03/2024 Using Data to Improve Understanding of Relationships between Proteins and Diseases Working with a new Emmy Noether Group, Dr. Pascal Schlosser is investigating how machine learning can aid in understanding the complex relationships between genes, proteins, and diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-data-improve-understanding-relationships-between-proteins-and-diseases
Press release - 02/02/2024 Epigenetic status determines metastasis Scientists from the German Cancer Research Center (DKFZ) and Medical Faculty Mannheim of the Heidelberg University investigated in mice how spreading tumor cells behave at the site of metastasis: Some tumor cells immediately start to form metastases. Others leave the blood vessel and may then enter a long period of dormancy. What determines which path the cancer cells take is their epigenetic status. https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetischer-status-entscheidet-ueber-metastasierung
Press release - 04/01/2024 Key player in viral heart inflammation discovered Inflammation of the heart muscle, also known as myocarditis, is a serious consequence of a viral infection. This can impede the heart’s ability to pump blood in the long term. In a current study, researchers of the Faculty of Medicine of the University of Freiburg have discovered a new approach for treating myocarditis. https://www.gesundheitsindustrie-bw.de/en/article/press-release/key-player-viral-heart-inflammation-discovered
Press release - 06/11/2023 Improving the efficacy of cancer immunotherapy with modified CAR-T cells CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments are unsuccessful. A limiting factor of this very effective and safe therapy is that the cells used in the process quickly reach a state of exhaustion. Researchers at the University of Freiburg have now been able to prevent this exhaustion and thus significantly improve the effect of the therapy in a preclinical animal model.https://www.gesundheitsindustrie-bw.de/en/article/press-release/improving-efficacy-cancer-immunotherapy-modified-car-t-cells
High-resolution microscopy technology bypassing the diffraction limit - 26/10/2023 From micro- to nanoscope It has long been impossible to distinguish objects closer than 200 nanometres using light microscopes. However, novel devices developed by a company called abberior Instruments GmbH, which use technology developed by Nobel Prize winner Prof. Dr. Stefan Hell and his teams in Heidelberg and Göttingen, are now able to bypass this resolution limit and provide detailed insights into living cells in the lower nanometre range.https://www.gesundheitsindustrie-bw.de/en/article/news/micro-nanoscope
Press release - 26/10/2023 Innovative research aims to improve wound healing and cancer therapy Jun.-Prof. Dr. Priscilla Briquez, junior professor at the Department of General and Visceral Surgery at the Freiburg University Medical Center and member of the Medical Faculty at the University of Freiburg, has received a European Research Council (ERC) Starting Grant from the European Commission. Her DRESSCODE project will receive a total of 1.5 million euros funding for five years.https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-forschung-soll-wundheilung-und-krebstherapie-verbessern
Press release - 25/10/2023 Epigenetically acting drugs could support cancer immunotherapy Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetically-acting-drugs-could-support-cancer-immunotherapy
Press release - 25/10/2023 Epigenetically acting drugs could support cancer immunotherapy Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetisch-wirkende-medikamente-koennten-krebs-immuntherapie-unterstuetzen
Press release - 18/10/2023 SARS-CoV-2: Alert immune system in the respiratory tract protects children from severe courses of the disease Why are severe courses of SARS-CoV-2 infection less common in children and adolescents than in adults? Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered that the immune system in the upper respiratory tract is much more alert and active in children before infection than in adults and is therefore better equipped to fight the virus.https://www.gesundheitsindustrie-bw.de/en/article/press-release/sars-cov-2-aktiveres-immunsystem-den-atemwegen-schuetzt-kinder-vor-schweren-verlaeufen
Press release - 04/10/2023 Therapeutic option for tumor patients with the rare DNAJB1-PRKACA gene fusion A phase I clinical trial is now starting at Tuebingen University Hospital in the Clinical Collaboration Unit (CCU) Translational Immunology, in collaboration with the Department of Internal Medicine I, which is investigating the therapeutic cancer peptide vaccine Fusion-VAC-XS15 in combination with immune checkpoint blockade by atezolizumab (Tecentriq®). https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapeutic-option-tumor-patients-rare-dnajb1-prkaca-gene-fusion
Press release - 19/09/2023 Better distinguish chronic inflammation and cancer of the pancreas Current diagnostic methods do not always reliably distinguish between chronic inflammation of the pancreas and pancreatic cancer. About one third of all diagnoses are inconclusive. Scientists from the German Cancer Research (DKFZ) and from Heidelberg University Hospital (UKHD) therefore searched for molecular markers that could specify this diagnosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/chronische-entzuendung-und-krebs-der-bauchspeicheldruese-praeziser-unterscheiden
Press release - 10/08/2023 Computer-aided cell analysis for faster diagnosis of blood diseases Scientists from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an AI system that recognizes and characterizes white and red blood cells in microscopic images of blood samples. The algorithm can help physicians diagnose blood disorders and is available as an open source method for research purposes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/computergestuetzte-zellanalyse-fuer-die-schnellere-diagnose-von-blutkrankheiten
Tumour organoids facilitate drug discovery - 20/07/2023 Drug screening for children with cancer using patient-specific miniature tumours Standard drugs often don’t work in children and adolescents with recurrent cancer. Researchers from the Hopp Children's Tumour Centre (KITZ) and the German Cancer Research Center (DKFZ) in Heidelberg have been looking to open up new therapy options for those affected, and have cultivated individual miniature tumours from biopsy samples to test the effectiveness of a variety of drugs within a few weeks.https://www.gesundheitsindustrie-bw.de/en/article/news/drug-screening-children-cancer-using-patient-specific-miniature-tumours
Press release - 20/06/2023 Tuberculosis Therapy: Smallest Particles Will Deliver the Drug to the Lungs in Future KIT and Research Center Borstel Present Nanoparticles with a High Antibiotic Concentration for Inhalation – Nanocarriers of Antibiotics Can Reduce Resistances and Enhance Compatibility.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tuberculosis-therapy-smallest-particles-will-deliver-drug-lungs-future
Press release - 16/06/2023 What determines whether breast cancer cells can form metastases? In most cancers, it is not the growth of the primary tumor that determines the prognosis for the patient, but whether it will spread and form metastases. This process is very complex. There are often years between the development of the cancer and the aggressive growth of the metastases. Scientists from the DKFZ, the HI-STEM, the Ruhr University Bochum, Helmholtz Munich and ETH Zurich have studied and identified metastasis growth in breast cancerhttps://www.gesundheitsindustrie-bw.de/en/article/press-release/what-determines-whether-breast-cancer-cells-can-form-metastases
Press release - 05/06/2023 New findings about human metabolic processes Researchers at the Faculty of Medicine at the University of Freiburg have gained significant new insights into metabolic processes in the kidney. The scientists from the Institute of Genetic Epidemiology at the Medical Center - University of Freiburg measured tiny molecules, so-called metabolites, which occur in blood and urine and reflect our metabolism, in samples from more than 5,000 study participants.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-about-human-metabolic-processes
Reduced immunosuppression possible in transplantations - 05/06/2023 Modified immune cells produce donor-specific tolerance Traditionally, transplant recipients have had to take immunosuppressive medication for life to prevent organ rejection. However, there are considerable side effects involved. Using modified immune cells (MICs), TolerogenixX GmbH from Heidelberg has now managed to generate donor-specific tolerance in recipients of living kidney transplants without suppressing the overall immune system.https://www.gesundheitsindustrie-bw.de/en/article/news/modified-immune-cells-produce-donor-specific-tolerance
Press release - 22/05/2023 Prevention of pandemics Volkswagen Foundation to fund international research project with around 1.5 million euros. Interdisciplinary team led by the Institute for Global Health at Heidelberg University Hospital to research the transmission of pathogens from animals to humans in Thailand and Laos. Long-term goal is to develop sustainable preventive measures against future pandemics.https://www.gesundheitsindustrie-bw.de/en/article/press-release/prevention-pandemics
Press release - 16/05/2023 Mast cells have an important impact on the development of chronic myeloid leukemia Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow. It mainly occurs in older individuals and represents about 20 percent of all adult leukemia cases. A research team from the Institute of Molecular Medicine and Cell Research at the University of Freiburg has now demonstrated for the first time that mast cells play a crucial role in the development of CML.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mast-cells-have-important-impact-development-chronic-myeloid-leukemia
Inovedis GmbH’s innovative implant - 28/03/2023 Next-generation minimally invasive shoulder surgery The treatment of shoulder injuries such as rotator cuff tears is one of the most common orthopaedic interventions. It is therefore quite surprising that the surgical procedure has not changed much for decades - although it is relatively complicated. The start-up Inovedis has now developed a completely new surgical technique based on an implant that can be performed simply, safely, quickly and cost-effectively with minimal stress for patients.https://www.gesundheitsindustrie-bw.de/en/article/news/next-generation-minimally-invasive-shoulder-surgery
Development of anti-tumour agents - 20/03/2023 Targeting the protective shield of cancers Cancer cells have different mechanisms to help them escape destruction by the immune system. Solid tumours, for example, are often surrounded by a protective layer of lactate, which has a strong immunosuppressive effect. WMT AG from Heidelberg is developing small drug molecules that reduce lactate production and thus make cancer cells vulnerable to immune system attacks.https://www.gesundheitsindustrie-bw.de/en/article/news/targeting-protective-shield-cancers
Press release - 13/03/2023 AI and multispectral imaging facilitate keyhole surgery How can camera images be used during minimally invasive surgeries to assess whether the operated organ is sufficiently perfused with blood? Scientists from the German Cancer Research Center (DKFZ) and the Städtisches Klinikum Karlsruhe have now succeeded in automatic monitoring of ischemia during a kidney surgery using only the optical properties of the tissue and not relying on injection of contrast agent. https://www.gesundheitsindustrie-bw.de/en/article/press-release/ki-und-moderne-bildgebung-erleichtern-schluesselloch-chirurgie
Press release - 01/03/2023 Pseudomonas aeruginosa Bacteria produce a molecule that paralyzes immune system cells Bacteria of the species Pseudomonas aeruginosa are antibiotic-resistant hospital germs that can enter blood, lungs and other tissues through wounds and cause life-threatening infections. In a joint project, researchers from the Universities of Freiburg and Strasbourg in France have discovered a mechanism that likely contributes to the severity of P. aeruginosa infections.https://www.gesundheitsindustrie-bw.de/en/article/press-release/pseudomonas-aeruginosa-bakterien-stellen-ein-molekuel-her-das-zellen-des-immunsystems-laehmt
Press release - 06/02/2023 Fewer side effects thanks to personalised medicine Patients have 30 percent fewer serious side effects when medication doses are tailored to their genetic profile. This is what an international research consortium has found out, including the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology at the Bosch Health Campus. With an individual DNA medication pass, as used in the study, treatments can be made more effective and safer in the future.https://www.gesundheitsindustrie-bw.de/en/article/press-release/weniger-nebenwirkungen-dank-personalisierter-medizin
Photon-counting technology - 01/02/2023 PC3 consortium: innovative computed tomography for Baden-Württemberg The University Hospitals of Freiburg, Tübingen and Mannheim have been cooperating with each other since 2021 to test new types of computed tomography devices. With the help of photon-counting technology, the aim is not only to improve patient care, but also to encourage local companies to develop downstream data processing technologies.https://www.gesundheitsindustrie-bw.de/en/article/news/pc3-consortium-innovative-computed-tomography-baden-wuerttemberg